Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosisFootnote

Peer review under responsibility of Alexandria University Faculty of Medicine.

Footnote

Available online 17 October 2014

References

• European Association for the Study of the LiverEASL Clinical Practice Guidelines: management of hepatitis C virus infectionJ Hepatol602014392420
   PubMed Web of Science ®Google Scholar
• F.El-ZanatyWay A.EgyptDemographic and health survey, 20092008Ministry of Health, El-Zanaty and Associates, and Macro InternationalCairo
   Google Scholar
• S.C.RayR.R.ArthurA.CarellaJ.BukhD.L.ThomasGenetic epidemiology of hepatitis C virus throughout EgyptJ Infect Dis18232000698707
   PubMed Web of Science ®Google Scholar
• J.H.HoofnagleCourse and outcome of hepatitis CHepatology365 Suppl. 12002S21S29
   PubMed Web of Science ®Google Scholar
• J.G.McHutchisonE.J.LawitzM.L.ShiffmanA.J.MuirG.W.GallerJ.McConePeginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionN Engl J Med3612009580593
   PubMed Web of Science ®Google Scholar
• D.GeJ.FellayA.J.ThompsonJ.S.SimonK.V.ShiannaT.J.UrbanGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature4612009399401 [PMID: 19684573 DOI: 10.1038/nature08309]
   PubMed Web of Science ®Google Scholar
• A.C.LyraS.RamrakhianiB.R.BaconA.M.Di BisceglieInfection with hepatitis C virus genotype 4 in the United StatesJ Clin Gastroenterol38120046871
   Web of Science ®Google Scholar
• L.Van AstenI.VerhaestS.LamziraI.Hernandez-AguadoR.ZangerleF.BoufassaSpread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysisJ Infect Dis18922004292302
   Web of Science ®Google Scholar
• C.PayanF.Roudot-ThoravalP.MarcellinN.BledG.DuverlieI.Fouchard-HubertChanging of hepatitis C virus genotype patterns in France at the beginning of the third millennium: The GEMHEP GenoCII StudyJ Viral Hepatol1242005405413
   Web of Science ®Google Scholar
• E.DegasperiA.AghemoClinical drivers in naïve patient eligibility for treatment of chronic hepatitis CJ Viral Hepat191201236
   Google Scholar
• P.Y.BochudS.BibertF.NegroB.HaagmansA.SoulierC.FerrariIL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis CJ Hepatol552011980988 [PMID: 21354446 DOI: 10.1016/j.jhep.2011.01.050]
   PubMed Web of Science ®Google Scholar
• E.JablonowskaA.PiekarskaE.Koslinska-BerkanA.OmuleckaB.SzymanskaK.WojcikSustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirinActa Biochim Polon5932012333337
   Web of Science ®Google Scholar
• J.Ordi-RosJ.VillarrealF.MonegalS.SauledaI.EstebanD.GeGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature4612009399401
   Web of Science ®Google Scholar
• J.G.McHutchisonD.B.GoldsteinM.CarringtonGenetic variation in IL28B and spontaneous clearance of hepatitis C virusNature4612009798801 [PMID: 19759533 DOI: 10.1038/nature08463]
   Web of Science ®Google Scholar
• A.CieslaM.Bociaga-JasikI.Sobczyk-KrupiarzM.K.GlowackiD.OwczarekD.CiborIL28B polymorphism as a predictor of antiviral response in chronic hepatitis CWorld J Gastroenterol1835201248924897
   Web of Science ®Google Scholar
• M.A.KhattabP.FerenciS.J.HadziyannisM.ColomboM.P.MannsP.L.AlmasioManagement of hepatitis C virus genotype 4: recommendations of an international expert panelJ Hepatol546201112501262
   PubMed Web of Science ®Google Scholar
• K.DomagalskiM.PawlowskaA.TretynW.HalotaM.PilarczykE.SmukalskaImpact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4Eur J Clin Microbiol Infect Dis32201374575410.1007/s10096-012-1799-z
   PubMed Web of Science ®Google Scholar
• P.BedossaT.PoynardAn algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study GroupHepatology2421996289293
   PubMed Web of Science ®Google Scholar
• M.G.GhanyD.B.StraderD.L.ThomasL.B.SeeffDiagnosis, management and treatment of hepatitis C: an updateHepatology49420091335137410.1002/hep.22759
   PubMed Web of Science ®Google Scholar
• J.A.PinedaA.CaruzA.RiveroK.NeukamI.SalasA.CamachoPrediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virusClin Infect Dis5172010788795
   PubMed Web of Science ®Google Scholar
• S.M.KamalC.S.GrahamQ.HeL.BianchiA.A.TawilJ.W.RasenackKinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosisJ Infect Dis189200411401150 [PMID: 15031780 DOI: 10.1086/382278]
   PubMed Web of Science ®Google Scholar
• H.Al AshgarA.HelmyM.Q.KhanK.Al KahtaniM.Al QuaizM.RezeigPredictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Ann Saudi Med2912009414
   Web of Science ®Google Scholar
• M.KhairyR.FouadM.MabroukW.El-AkelA.AwadR.SalamaThe impact of Interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected Egyptian patients using data mining analysisHepat Mon1372013e1050910.5812/hepatmon.10509
   Web of Science ®Google Scholar
• X.Jun-qiangG.Xiao-yanZ.Xiao-hongL.Bing-liangX.Dong-yingG.Zhi-liangRelationship between the genetic variation in interleukin 28B and response to antiviral therapy in patients with chronic hepatitis CChin Med J12513201223342338
   Web of Science ®Google Scholar
• S.De NicolaA.AghemoM.G.RumiE.GalmozziL.ValentiR.SoffrediniInterleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4Hepatology5522012336342
   PubMed Web of Science ®Google Scholar
• T.AsselahS.De MuynckP.BroetJ.Masliah-PlanchonM.BlanluetI.BiecheIL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis CJ Hepatol5632012527532
   PubMed Web of Science ®Google Scholar
• M.K.El-AwadyL.MostafaA.A.TabllT.H.AbdelhafezN.G.Bader El DinN.ZayedAssociation of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver diseaseHepat Mon1242012271277
   PubMed Web of Science ®Google Scholar
• M.R.CharltonA.ThompsonB.J.VeldtK.WattH.TillmannJ.J.PoteruchaInterleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infectionHepatology532011317324
   PubMed Web of Science ®Google Scholar
• C.FabrisE.FalletiA.CussighD.BitettoE.FontaniniS.BignulinIL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCCJ Hepatol542011716722
   PubMed Web of Science ®Google Scholar
• M.Martinot-PeignouxC.SternS.MaylinM.P.RipaultN.BoyerL.LeclereTwelve weeks post treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirinJ Hepatol602014392420
   Google Scholar
• F.HasanH.AskerJ.Al-KhaldiI.SiddiqueM.Al-AjmiS.OwaidPeginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4Am J Gastroenterol999200417331737
   Web of Science ®Google Scholar
• R.MoucariM.P.RipaultM.Martinot-PeignouxH.VoitotA.C.CardosoC.SternInsulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4Gut5812200916621669
   PubMed Web of Science ®Google Scholar
• Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, et al. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. BioMed Res Int 2013; Article ID 580796, 6 pages.
   Google Scholar
• A.J.ThompsonA.J.MuirM.S.SulkowskiInterleukin28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusGastroenterology13912010120129
   PubMed Web of Science ®Google Scholar
• S.M.KamalS.S.El KamaryM.D.ShardellM.HashemI.N.AhmedM.MuhammadiPegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic responseHepatology466200717321740
   Web of Science ®Google Scholar
• R.R.GadS.MalesH.El MakhzangyS.ShoumanA.HasanM.AttalaPredictors of a sustained virological response in patients with genotype 4 chronic hepatitis CLiver Int288200811121119
   PubMed Web of Science ®Google Scholar
• A.RauchZ.KutalikP.DescombesT.CaiJ.Di IulioT.MuellerGenetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyGastroenterology1384201013381345
   PubMed Web of Science ®Google Scholar
• J.J.McCarthyJ.H.LiA.ThompsonS.SuchindranX.Q.LaoK.PatelReplicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirinGastroenterology1387201023072314
   PubMed Web of Science ®Google Scholar
• M.Romero-GomezM.EslamA.RuizM.MaraverGenes and hepatitis C: susceptibility, fibrosis progression and response to treatmentLiver Int312011443460
   PubMed Web of Science ®Google Scholar
• M.Abdel-RahmanM.El-SayedM.El RazikyA.ElsharkawyW.El-AkelH.GhoneimCoinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment responseWorld J Gastroenterol1917201326912696
   PubMed Web of Science ®Google Scholar
• M.C.CorreiaA.L.DominguesH.R.LacerdaE.M.SantosC.G.MachadoV.HoraPlatelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoniTrans R Soc Trop Med Hyg103200910531058
   PubMed Web of Science ®Google Scholar
• H.H.GadC.DellgrenO.J.HammingS.VendsS.R.PaludanR.HartmannInterferon-lambda is functionally an interferon but structurally related to the interleukin-10 familyJ Biol Chem2843120092086920875
   PubMed Web of Science ®Google Scholar
• S.MalesR.R.GadG.EsmatH.AbobakrM.AnwarC.RekacewiczSerum alpha-fetoprotein level predicts treatment outcome in chronic hepatitis CAntivir Ther1252007797803
   Web of Science ®Google Scholar
• N.AkutaF.SuzukiY.KawamuraH.YatsujiH.SezakiY.SuzukiPredictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1bJ Med Virol7911200716851686
   Web of Science ®Google Scholar
• T.M.ChenP.T.HuangM.H.TsaiL.F.LinC.C.LiuK.S.HoPredictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapyJ Gastroenterol Hepatol2252007669675
   PubMed Web of Science ®Google Scholar
• H.AbdoulV.MalletS.PolA.FontanetSerum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotypePLoS One362008e239110.1371/journal.pone.0002391
   Web of Science ®Google Scholar